Skip To The Main Content

Asia Litigation

Over the course of the last several decades, clients have benefited from Simpson Thacher establishing one of the leading transactional practices in Asia—with offices in Beijing, Hong Kong and Tokyo. As globalization intensified, and the transactional activities of our clients increased, they needed representation in Trans-Pacific litigation, and regulatory and investigative matters. Our Asia Litigation Practice serves our clients in this rapidly expanding market.

“They are so responsive and so thoughtful. The service and responsiveness is through the roof.”
Chambers USA (quoting a client)

Clients seek the advice of our Asia Litigation Practice primarily for securities litigation, government and internal investigations, international arbitration, and antitrust and trade regulation. Our team includes attorneys with extensive experience in Asia-related litigation, including many who are fluent in Chinese, Japanese or Korean. Clients rely on our ability to obtain successful, cost-effective outcomes, and appreciate our understanding of the interplay of economic, legal and cultural issues arising in litigation, arbitration and investigation matters. We are pleased that these successes have earned us the trust and loyalty of numerous leading companies with business interests in Asia.

Select disputes include:

  • Alibaba in multibillion-dollar securities class action alleging false and misleading statements in prospectus for its record-setting $25 billion IPO; and separately, in securities class action related to Ant Group’s IPO
  • JOYY in Ninth Circuit affirmation of a complete dismissal of a securities class action
  • Daiichi Sankyo in securing a final award of approximately US$525 million on a fraud claim in ICC arbitration in Singapore
  • Qutoutiao in dismissal of securities class action
  • Yalla Group in complete dismissal of a securities class action
  • Qudian Inc. in dismissal of putative securities class action
  • Ruhnn in dismissal of securities class actions concerning its IPO disclosures
  • GDS Holdings Limited in dismissal of securities class action
  • Full Truck Alliance (“FTA”) in a Securities Act class action
  • Ant Financial (n/k/a Ant Group) in shareholder litigation related to its $1.2 billion acquisition of Moneygram
  • Yingli in obtaining complete dismissal in federal securities lawsuit; and in antitrust litigations alleging price fixing in the solar panel market
  • Xunlei Limited in securities class action based on the strategic divestment of an online video streaming business and focus on mobile Internet services
  • Publicly traded Chinese energy company in LCIA arbitration concerning major supply agreement dispute
  • Wanda Sports in dismissal of securities class action lawsuit related to its IPO
  • Leading global private equity firms in M&A and other HKIAC, ICC, and CIETAC arbitrations, both in the capacities of claimant and respondent
Show more

Select government and internal investigations include:

  • Audit committee of a Chinese automotive energy company in an investigation into possible corruption and bribery issues in China
  • Global charitable organization in internal investigation relating to suspected corruption in operations in India
  • A senior executive of a global shipping company in a DOJ criminal investigation involving China, Japan and Brazil
  • Global financial institution in SEC, FINRA and U.S. Department of Treasury investigations in connection with securities offerings by a China-based public company listed in the U.S.
  • U.S.-based non-profit in connection with a congressional investigation arising out of its China program and compliance with the Foreign Agent Registration Act
  • Leading global e-commerce company in connection with an SEC investigation into certain accounting, related-party transaction, and other disclosure matters
  • Global promotion products supplier and senior executive subject to DOJ indictment for price fixing
  • Multinational medical technologies company as SEC-appointed independent consultant relating to FCPA internal control failures 
  • Leading global pharmaceutical manufacturer in global anti-corruption investigation focused on alleged misconduct in China and other jurisdictions
  • U.S.-listed consumer products company in internal investigation relating to potential corruption in China operations, as well as a follow-up review of the company’s global compliance program
Show more
“One of the strengths of this team is the amount of work they do in China, so they have a particular understanding of the unique challenges and issues there.”
Chambers USA

    News & Events

      Publications